Abstract Similar articles
ntroduction: Peginterferon has an increased plasma half-life and enables a constant exposure to interferon. This modification might increase the antiangiogenic effect of the treatment andI influence the efficacy. We report the results of a phase II open-label study with Peginterferon alfa-